Andrea Tan
Stock Analyst at Goldman Sachs
(0)
# 3189
Out of 3,975 analysts
46
Total ratings
43.48%
Success rate
-6.52%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Tarsus Pharmaceutica... | Maintains: Neutral | 36 41 | 55.99 | -26.77% | 3 | Nov 15, 2024 | |
Insmed | Maintains: Strong Buy | 74 102 | 69.96 | 45.8% | 9 | Jul 10, 2024 | |
Sagimet Biosciences | Maintains: Neutral | 23 6 | 4.98 | 20.48% | 5 | Jul 1, 2024 | |
Arrowhead Pharma | Initiates Coverage On: Neutral | 31 | 19.86 | 56.09% | 1 | Jun 5, 2024 | |
Relmada Therapeutics | Downgrades: Sell | 3 2 | 0.48 | 316.67% | 3 | Jun 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 19 21 | 7.62 | 175.59% | 4 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 50 44 | 12.68 | 247% | 4 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reinstates: Sell | 2 | 9.07 | -77.95% | 1 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | 17 | n/a | n/a | 1 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 160 | 158.37 | 1.03% | 1 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 27 24 | 3.13 | 666.77% | 2 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Sell | 10 4 | 1.81 | 120.99% | 2 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 178 375 | 320.04 | 17.17% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Sell | 13 | 6.26 | 107.67% | 1 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 2 2 | n/a | n/a | 6 | Nov 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 6 4 | 1.29 | 210.08% | 2 | May 24, 2022 |